Last Price$19.1(7.5%)
Market Cap$14.6B
N/A
Peers median - 18.9%
N/A
Peers median - 14.8%
1.9%
Peers median - 5.2%
(3,335.4%)
Peers median - (9.9%)
Competing with SMMT
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$14.6B | 5.9 | $0.5 97.4% overvalued | 327.0% | $0.0 | ($142.1M) | N/A | N/A | N/A | (3,335.4%) | 1.9% | |
$402.0B | 6.7 | $60.0 32.9% overvalued | (29.6%) | DKK 290.4B | DKK 70.0B | 25.0% | 24.1% | 84.7% | 35.5% | 71.6% | |
$125.5B | 5.7 | $195.0 59.6% overvalued | 14.0% | $11.0B | ($790.3M) | 11.5% | (7.2%) | 86.1% | (15.0%) | 10.7% | |
$74.0B | 6.5 | $1,013.8 48.0% undervalued | (29.5%) | $14.2B | $3,597.2M | 8.3% | 25.3% | 86.7% | 25.0% | 5.7% | |
$38.1B | 5.8 | $109.1 82.5% overvalued | 59.5% | $2,258.9M | ($211.2M) | 127.3% | (9.4%) | 86.8% | (41.3%) | N/A | |
$31.3B | 5.2 | $93.6 61.6% overvalued | 62.3% | $2,248.2M | ($42.6M) | 23.0% | (1.9%) | 85.6% | (7.2%) | 1,931.9% | |
$27.1B | 6.3 | $165.8 48.6% undervalued | 24.9% | €3,040.1M | €985.3M | (54.1%) | 32.4% | 84.3% | (41.4%) | 1.3% | |
$15.2B | 5.6 | $179.7 430.9% undervalued | 15.9% | $2,263.9M | $2,769.5M | (3.8%) | 122.3% | 73.9% | 14.5% | 0.0% | |
$14.8B | 5.6 | $46.7 33.6% overvalued | 17.6% | $4,241.2M | $235.2M | 14.8% | 5.5% | 92.3% | (12.7%) | 1.3% | |
$14.0B | 7.7 | $427.2 37.8% undervalued | 35.5% | $2,877.4M | $1,080.6M | 23.6% | 37.6% | 89.2% | 65.4% | 4.7% | |
$1,846.9M | 5.4 | $2,805.1 1,137.3% undervalued | 39.9% | $3,316.8M | ($1,009.2M) | 50.5% | (30.4%) | 83.1% | (38.4%) | 32.1% |
Compare SMMT Valuation Multiples with Peers
LTM
NTM
1Y Forward
2Y Forward
EV/Revenue
General
Valuation Multiple
Financial metrics
Company name
EV/Revenue
Revenue growth
EBITDA margin
Net Income margin
Summit Therapeutics Inc.SMMT
N/A
N/A
(68.7%)
N/A
Median Peer Set
4.0x
18.9%
(41.2%)
12.6%
Alnylam Pharmaceuticals, Inc.ALNY
13.3x
23.0%
(38.6%)
(12.4%)
argenx SEARGX
N/A
198.6%
(60.5%)
(24.1%)
BeiGene, Ltd.BGNE
0.1x
73.7%
(56.5%)
(35.9%)
BioNTech SEBNTX
3.1x
(77.4%)
(89.7%)
24.4%
Incyte CorporationINCY
3.0x
14.8%
(94.0%)
0.8%
Novo Nordisk A/SNVO
10.2x
24.9%
142.8%
34.8%
Regeneron Pharmaceuticals, Inc.REGN
4.1x
8.3%
10.4%
31.1%
Royalty Pharma plcRPRX
6.3x
(3.8%)
(43.7%)
37.9%
United Therapeutics CorporationUTHR
3.8x
23.6%
25.7%
41.5%
Vertex Pharmaceuticals IncorporatedVRTX
11.0x
11.7%
N/A
(4.9%)
Compare SMMT Valuation Multiples Dynamics with Peers
Crunching data... Almost there!
FAQ
1. How does Summit Therapeutics Inc. (SMMT) revenue growth compare to peers and the industry?
Summit Therapeutics Inc. (SMMT) revenue growth is N/A, compared to the peers' median of 18.9%.
2. How does Summit Therapeutics Inc. (SMMT) Free Cash Flow (FCF) margin compare to peers and the industry?
Summit Therapeutics Inc. (SMMT) FCF margin is N/A, compared to the peers' median of 14.8%.
3. How does Summit Therapeutics Inc. (SMMT) Total Debt to Equity ratio compare to peers and the industry?
Summit Therapeutics Inc. (SMMT) Total Debt to Equity ratio is 1.9%, compared to the peers' median of 5.2%.
4. How does Summit Therapeutics Inc. (SMMT) ROIC (Return on Invested Capital) compare to peers and the industry?
Summit Therapeutics Inc. (SMMT) ROIC is (3,335.4%), compared to the peers' median of (9.9%).